JPM22, Day 3: Eli Lilly weighs dual branding for diabetes hopeful tirzepatide

JPM22, Day 3: Eli Lilly weighs dual branding for diabetes hopeful tirzepatide
fkansteiner
Wed, 01/12/2022 – 08:12